

This is the peer reviewed version of the following article:

Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis / Cocconcelli, E; Tonelli, R; Abbati, G; Marchioni, A; Castaniere, I; Pelizzaro, F; Russo, Fp; Vegetti, A; Balestro, E; Pietrangelo, A; Richeldi, L; Luppi, F; Spagnolo, P; Clini, E; Cerri, S.. - In: INTERNAL AND EMERGENCY MEDICINE. - ISSN 1970-9366. - 16:2(2021), pp. 349-357. [10.1007/s11739-020-02376-2]

Terms of use:

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

04/07/2024 10:04

(Article begins on next page)

Internal and Emergency Medicine

Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis

--Manuscript Draft--

Manuscript Number:	IAEM-D-20-00198
Full Title:	Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis
Article Type:	ORIGINAL
Section/Category:	IM - ORIGINAL
Keywords:	lung fibrosis, liver fibrosis, hepatic transient elastography
Corresponding Author:	Enrico M. Clini, MD University of Modena and Reggio, Italy ITALY
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	University of Modena and Reggio, Italy
Corresponding Author's Secondary Institution:	
First Author Secondary Information:	
First Author:	Elisabetta Cocconcelli
Order of Authors:	Elisabetta Cocconcelli
	Roberto Tonelli
	Gianluca Abbati
	Alessandro Marchioni
	Ivana Castaniere
	Filippo Pelizzaro
	Francesco Paolo Russo
	Alberto Veggetti
	Elisabetta Balestro
	Antonello Pietrangelo
	Luca Richeldi
	Fabrizio Luppi
	Paolo Spagnolo
	Enrico M. Clini, MD
	Stefania Cerri
Order of Authors Secondary Information:	
Funding Information:	
Abstract:	<p>Background - Data on the presence of subclinical fibrosis across multiple organs in patients with idiopathic lung fibrosis (IPF) are lacking. Our study aimed at investigating through hepatic transient elastography (HTE) the prevalence and clinical impact of subclinical liver fibrosis in a cohort of patients with IPF.</p> <p>Methods - Patients referred to the Centre for Rare Lung Disease of the University Hospital of Modena (Italy) from March 2012 to February 2013 with established diagnosis of IPF and without a documented history of liver diseases were consecutively enrolled and underwent HTE. Based on hepatic stiffness status as assessed through METAVIR score patients were categorized as " with liver fibrosis "</p>

	<p>(corresponding to a METAVIR score of F1-F4) and “ without liver fibrosis” (METAVIR F0). Potential predictors of liver fibrosis were investigated through logistic regression model among clinical and serological variables. The overall survival (OS) was assessed according to liver fibrosis and multivariate Cox regression analysis was used to identify independent predictors.</p> <p>Results - In 13 out of 37 patients (35%) with IPF a certain degree of liver fibrosis was documented.No correlation was found between liver stiffness and clinical-functional parameters. OS was lower in patients ‘ with liver fibrosis’ than in patients ‘ without liver fibrosis’ (median months 33[23-55] vs. 63[26-94], p=0.038). Patients ‘ with liver fibrosis’ presented a higher risk of death at seven years as compared to patients ‘ without liver fibrosis’ (HR=2.6, 95%CI[1.003–6.7],p= 0.049). Higher level of AST to platelet ratio Index (APRI)was an independent predictor of survival (HR=4.52 95%CI[1.3–15.6], p=0.02).</p> <p>Conclusions - In our cohort, more than one third of IPF patients had concomitant subclinical liver fibrosis that negatively affected OS. These preliminary claims further investigation aimed at clarifying the mechanisms beyond multiorgan fibrosis and its clinical implication in patients with IPF.</p>
<p>Suggested Reviewers:</p>	<p>Carlo Vancheri carlo.vancheri@unict.it</p>

Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis

1
2
3
4 Elisabetta Cocconcelli¹, Roberto Tonelli^{2,3}, Gianluca Abbati⁴, Alessandro Marchioni², Ivana
5
6 Castaniere^{2,3}, Filippo Pelizzaro⁵, Francesco Paolo Russo⁵, Alberto Veggetti⁴, Elisabetta Balestro¹,
7
8 Antonello Pietrangelo⁴, Luca Richeldi⁶, Fabrizio Luppi⁷, Paolo Spagnolo¹, Enrico Clini², Stefania Cerri²
9

- 10
11
12
13
14 1. University Hospital of Padova, Department of Cardiac, Thoracic, Vascular Sciences and Public
15
16 Health. Padova (I).
- 17
18
19 2. University Hospital of Modena, Respiratory Diseases Unit and Centre for Rare Lung Diseases,
20
21 Dpt of Medical and Surgical Sciences, University of Modena Reggio Emilia. Modena (I).
- 22
23
24 3. Clinical and Experimental Medicine PhD Program, University of Modena Reggio Emilia,
25
26 Modena (I).
- 27
28
29 4. University Hospital of Modena, Internal Medicine Unit, Dpt of Medical and Surgical Sciences,
30
31 University of Modena Reggio Emilia. Modena (I).
- 32
33
34 5. Department of Surgical, Oncological and Gastroenterological Sciences, Unit of
35
36 Gastroenterology, University of Padova, Italy.
- 37
38
39 6. University Cattolica del Sacro Cuore, Respiratory Diseases Unit, University Hospital Agostino
40
41 Gemelli, Roma. (I).
- 42
43
44 7. Respiratory Unit, University of Milano Bicocca, S. Gerardo Hospital, Monza, Italy
45
46
47
48
49

50 Elisabetta Cocconcelli: ecocconcelli@icloud.com

51
52 Roberto Tonelli: roberto.tonelli@me.com

53
54 Gianluca Abbati: abbati.gianluca@policlinico.mo.it

55
56 Alessandro Marchioni: marchioni.alessandro@unimore.it
57
58
59
60
61
62
63
64
65

Ivana Castaniere: ivana.castaniere@unimore.it

1 Filippo Pelizzaro: filippo.pelizzaro@gmail.com

2
3
4 Francesco Paolo Russo: francescopaolo.russo@unipd.it

5
6 Alberto Veggetti: veggetti.alberto@policlinico.mo.it

7
8
9 Elisabetta Balestro: elisabetta_balestro@hotmail.com

10
11 Antonello Pietrangelo: antonello.pietrangelo@unimore.it

12
13
14 Luca Richeldi: luca.richeldi@unicatt.it

15
16
17 Fabrizio Luppi: fabrizio.luppi@unimore.it

18
19
20 Paolo Spagnolo: paolo.spagnolo@unipd.it

21
22 Enrico M Clini: enrico.clini@unimore.it

23
24
25 Stefania Cerri: stefania.cerri@unimore.it

26
27
28
29 Corresponding author:

30
31
32 Prof. Enrico Clini

33
34 University of Modena & Reggio Emilia

35
36 Chair of Respiratory Medicine

37
38 Director Post-doctoral School in Respiratory Medicine

39
40 Azienda Ospedaliera-Universitaria di Modena, Policlinico

41
42 Director, Pneumology Unit

43
44 Office +39 059 4222918

45
46 Secretary +39 059 4222198

47
48 enrico.clini@unimore.it

49
50 Skype enrico.clini

51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abbreviations list

1 BMI – Body Mass Index; TLC – Total Lung Capacity; FVC – Forced Vital Capacity; DLCO – Diffuse Lung
2
3
4 Capacity for Carbon Dioxide; GAP – Gender, Age, P pulmonary function (FVC, DLCO); PBC - primary
5
6 biliary cirrhosis; PSC - and primary sclerosing cholangitis; AMA - antimitochondrial antibody; ASMA
7
8 - anti-smooth muscle antibodies; AST - aspartate aminotransferase; ALT - alanine
9
10 aminostransferase; γ GT - gamma-glutamyl transpherase; IgG4 - immunoglobulin G4; APRI - AST to
11
12 platelet ratio Index.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abstract

Background

Data on the presence of subclinical fibrosis across multiple organs in patients with idiopathic lung fibrosis (IPF) are lacking. Our study aimed at investigating through hepatic transient elastography (HTE) the prevalence and clinical impact of subclinical liver fibrosis in a cohort of patients with IPF.

Methods

Patients referred to the Centre for Rare Lung Disease of the University Hospital of Modena (Italy) from March 2012 to February 2013 with established diagnosis of IPF and without a documented history of liver diseases were consecutively enrolled and underwent HTE. Based on hepatic stiffness status as assessed through METAVIR score patients were categorized as “*with liver fibrosis*” (corresponding to a METAVIR score of F1-F4) and “*without liver fibrosis*” (METAVIR F0). Potential predictors of liver fibrosis were investigated through logistic regression model among clinical and serological variables. The overall survival (OS) was assessed according to liver fibrosis and multivariate Cox regression analysis was used to identify independent predictors.

Results

In 13 out of 37 patients (35%) with IPF a certain degree of liver fibrosis was documented. No correlation was found between liver stiffness and clinical-functional parameters. OS was lower in patients ‘*with liver fibrosis*’ than in patients ‘*without liver fibrosis*’ (median months 33[23-55] vs. 63[26-94], $p=0.038$). Patients ‘*with liver fibrosis*’ presented a higher risk of death at seven years as compared to patients ‘*without liver fibrosis*’ (HR=2.6, 95%CI[1.003–6.7], $p=0.049$). Higher level of AST to platelet ratio Index (APRI) was an independent predictor of survival (HR=4.52 95%CI[1.3–15.6], $p=0.02$).

Conclusions

In our cohort, more than one third of IPF patients had concomitant subclinical liver fibrosis that negatively affected OS. These preliminary claims further investigation aimed at clarifying the mechanisms beyond multiorgan fibrosis and its clinical implication in patients with IPF.

Background

1 Fibrogenesis is a key mechanism of tissue repair representing a physiological response to injury (1).
2

3
4 In some pathological conditions, however, this pathway may result dysregulated so that undue
5
6 fibroproliferation and extracellular matrix deposition occur, leading to tissue injury and dysfunction
7
8
9 (2). Every tissue or organ may potentially be involved. While tissue specific injury has different
10
11 origin, responses to injury and repair mechanisms are similar across different organs (3). Many
12
13 distinct causes can contribute to the development of progressive fibrotic diseases, including genetic
14
15 abnormalities, infections, exposure to toxins or pollutants, micro-aspiration of gastric content,
16
17 tobacco smoke, chronic autoimmune inflammation (4).
18
19
20

21
22 In idiopathic pulmonary fibrosis (IPF), a specific form of chronic and progressive interstitial
23
24 pneumonia, repeated subclinical damages to alveolar epithelial cells (AECs) superimposed on
25
26 accelerated epithelial aging lead to abnormal healing processes and deposition of interstitial fibrosis
27
28 by fibroblasts and myofibroblasts (5,6). IPF represents a particularly arduous challenge, as, in
29
30 contrast to other forms of lung injury, knowledge about the inciting injury, progressive
31
32 fibroproliferation and lack of resolution are only partially understood (6-8). Consequently, there are
33
34 no therapies able to halt or reverse the fibrotic process of IPF.
35
36
37
38
39

40 Whether the activation of a fibrotic response in one organ might induce similar manifestations in
41
42 other organs, as a result of the activation of common pathways, is unknown. Specifically, robust
43
44 data about the co-existing presence of fibrotic disease across multiple organs in patients with IPF
45
46 are lacking. With this background, the aim of our study is to evaluate the prevalence and clinical
47
48 relevance of subclinical hepatic fibrosis through hepatic transient elastography (HTE) in patients
49
50 diagnosed with IPF without clinically overt liver disease.
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Materials and methods

Study population

We consecutively enrolled patients with established diagnosis of IPF referred to the Centre for Rare Lung Diseases of the University Hospital of Modena (Italy) over a 12-month period (from March 2012 to February 2013). Demographic, clinical and functional data (forced vital capacity [FVC] and diffusing capacity of the lung for carbon monoxide [DLCO]) were recorded at the time of diagnosis. Each patient started antifibrotic treatment (either pirfenidone or nintedanib) at diagnosis. Disease severity score of IPF patients was recorded using the GAP-staging system, which includes gender, age, FVC and DLCO (9).

The exclusion criteria were: documented history of chronic liver disease of known cause; positive screening for potential secondary causes of liver fibrosis including positive serology for chronic hepatitis B or C virus infection, history of alcohol abuse (> 2 units of alcohol), pharmacological treatments with prevalent hepatic metabolism, body mass index (BMI) > 29 kg/m², inability to express a valid informed consent.

The study was performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the University Hospital of Modena (Prot n. 2645). Informed consent was obtained for all study participants.

Liver stiffness evaluation

HTE was performed using Fibroscan[®] (Echosense[™], Paris, France) at the Hereditary and Metabolic Center for Liver Diseases of the University Hospital of Modena. The exam was performed by internal medicine physicians experienced in hepatic fibrosis who were blinded to the past medical history of each patient and to the design of the study. HTE was performed with patient lying flat on the back, with the right arm tucked behind the head to facilitate the access to the hepatic right lobe. The tip of the probe transducer was placed on the skin between the rib bones at the level of the right

hepatic lobe. Once the measurement area had been located, signal acquisition was started. The Fibroscan® internal software (Echosense™, Paris, France) determined whether each measurement was successful or not. The overall liver stiffness corresponded to a mean of 10 successful measurements and was expressed in kiloPascals (kPa). Liver stiffness values ranged from 2.5 to 75 kPa and were immediately available and operator-independent (10). Liver kPa stiffness threshold values were related to METAVIR parameters. In particular values range 0 - 5.2 kPa corresponded to METAVIR F0 (absence of fibrosis), range 5.3 kPa - 7.4 kPa to METAVIR F1 (fibrosis exist with expansion of portal zones – mild fibrosis), range 7.5 kPa-9 kPa to METAVIR F2 (fibrosis exist with expansion of most portal zones and occasional bridging – significant fibrosis), range 9.1 kPa - 13.1 kPa to METAVIR F3 (fibrosis exist with expansion of most portal zones and marked bridging and occasional nodules – severe fibrosis), range 13.2 kPa - 75 kPa to METAVIR F4 (cirrhosis) respectively (11).

Based on METAVIR parameters, IPF patients were categorized as ‘with liver fibrosis’ (if METAVIR value correspond to F1, F2, F3, F4) or ‘without liver fibrosis’ (if METAVIR value correspond to F0). All patients enrolled in the study were further investigated for liver disease. These investigations included autoantibodies for the autoimmune hepatitis, primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) (anti-nuclear antibodies [ANA], anti-Liver and Kidney Microsomes [anti-LKM] antibodies, antimitochondrial antibodies [AMA], anti-smooth muscle antibodies [ASMA]), serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (γ GT), bilirubin, iron, and circulating immunoglobulins G4 (IgG4). The AST to platelet ratio Index (APRI), a predictor of liver fibrosis, was calculated as follows: $AST / \text{upper limit of normal} \times 100 / \text{platelet count}$ (12,13).

Statistical analysis

Categorical variables are expressed as absolute (n) and relative values (%) whereas continuous variables as median and interquartile range (IQR). To compare demographic data and baseline clinical characteristics between IPF patients '*with liver fibrosis*' and IPF patients '*without liver fibrosis*', Chi square test and Fisher's exact test for categorical variables and Mann-Whitney U test for continuous variables were used, as appropriate.

The correlation between liver stiffness values in kPa and each serum parameter was assessed for the entire study population and in the two groups of IPF patients (with liver fibrosis and without liver fibrosis) with the nonparametric Spearman's rank method. Univariate logistic regression analysis was performed to detect predictors of liver fibrosis.

The overall survival (OS) was calculated from diagnosis to death or lung transplantation, with data censored at September 1st, 2019. The cumulative survival rate was calculated using Kaplan-Meier method and the difference in the survival time between the two groups ('*with liver fibrosis*' and '*without liver fibrosis*') was assessed with log-rank test. A multivariate Cox regression analysis was used to determine which clinical and serological features were independently associated with survival. Only variables with a statistically significant and almost significant ($0.05 < p < 0.09$) association with OS at the univariate analysis were included in the multivariate model.

All data were analysed using SPSS Software version 25.0 (New York, NY, US: IBM Corp. USA). P-values < 0.05 were considered statistically significant. The statistical package GraphPad Prism 7.0 (GraphPad Software, Inc. La Jolla, CA, USA) was used for graphs.

Results

Forty-eight consecutive IPF patients were considered and 37 were finally enrolled in the study (Table 1). In 29 patients (78%), HTE measurements for liver stiffness were considered reliable while for 8 patients (22%) HTE measurements were unsuccessful as the software could not determine a final mean measurement of liver stiffness from ten valid measurements. Sixteen out of the 29 patients (55%) had a median liver stiffness value of 3.65 kPa (range, 2.60 - 5.10 kPa) corresponding to a METAVIR value of F0 and were classified as '*without liver fibrosis*'. Four patients had a median liver stiffness of 6.70 kPa (6.10 – 7.40 kPa) corresponding to a METAVIR value of F1, six patients had a median liver stiffness of 7.70 kPa (7.60 – 8.40 kPa) corresponding to a METAVIR value of F2, one patient had a liver stiffness value of 9.50 kPa corresponding to a METAVIR value of F3 and two patients had a liver stiffness value of 14.30 and 45.30 kPa corresponding to a METAVIR value of F4. Patients with liver stiffness corresponding to a METAVIR value of F1-F2-F3-F4 formed the group of IPF patients '*with liver fibrosis*' (Figure 1). Demographics and functional data of the 29 patients evaluated for liver stiffness are presented in Table 2. Patients '*with liver fibrosis*' present lower age at diagnosis as compared to patients '*without liver fibrosis*' (66 years [54-78] vs. 75 years [42-83] respectively; $p = 0.04$), but the two groups were similar with regard to the demographic features (sex, smoking history, radiological diagnosis) as well as functional parameters (FVC, DLCO, GAP score) (Figure 1).

Serum analysis and correlations

Blood tests (AST, ALT, γ GT, platelets, total bilirubin, APRI index, IgG4, iron, ferritin and transferrin) were similar in patients '*with liver fibrosis*' and '*without liver fibrosis*' (Table 2). Notably, one of the two patients with F4 on HTE measurements had also high IgG4 levels (i.e. 419 mg/dL; normal values defined as lower than 86 mg/dL) and underwent liver biopsy, which revealed chronic idiopathic liver disease. No correlation between liver stiffness values (kPa) and clinical-functional parameters (age,

1 smoking history, FVC, DLCO, GAP score) or blood tests (AST, ALT, γ GT, APRI index, IgG4, ferritin and
2 transferrin) was found, neither in the entire study population of IPF patients evaluated for liver
3 fibrosis nor when it was stratified by presence/absence of liver fibrosis. Gender, functional data at
4 baseline, APRI test, and AST/ALT/ γ GT were not associated with liver stiffness at univariate logistic
5 regression (Table 3).
6
7
8
9

10 *Survival analysis*

11 Survival was estimates during a follow up time of 7 years, with median OS of 44 months. The OS of
12 patients '*with liver fibrosis*' was lower than patients '*without liver fibrosis*', with a median OS of 33
13 (23-55) months for patient '*with liver fibrosis*' and 63 (26-94) months for patients '*without liver*
14 *fibrosis*' ($p=0.038$) (Figure 2). Patients with liver fibrosis presented higher risk of death at seven years
15 as compared to patients without hepatic involvement (HR 2.6, 95% CI 1.003 – 6.7; $p= 0.049$, Figure
16 2) (Figure 3).
17
18
19
20
21
22
23
24
25
26
27
28

29 Univariate analysis of factors associated with survival revealed that lower DLCO at diagnosis, GAP
30 score III compared to GAP score I, presence of liver fibrosis and high levels of APRI score had a
31 significant negative association with survival in the whole IPF population (Table 4). Multivariate
32 analysis showed that only high level of APRI was an independent predictor of survival in our IPF
33 cohort (HR: 4.52 95%CI [1.3 – 15.6]; $p = 0.02$).
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Discussion

1 Our study aimed at non-invasively assessing whether IPF patients without a clinical overt liver
2 disease may present subclinical hepatic fibrosis. We found that IPF patients presented a significant
3 prevalence of liver fibrosis (35%) that negatively affected survival.
4
5
6

7
8 To our knowledge, robust evidences about the co-existing presence of fibrotic disease across
9 multiple organs in patients with IPF are lacking. Collagen deposition is an indispensable and typically
10 reversible part of wound healing, even though normal tissue repair can evolve into a progressive
11 and irreversible fibrotic response when tissue injury is severe or if the wound-healing response
12 results dysregulated (1,2,14). A feature shared by all fibrotic diseases is the activation and
13 differentiation of fibroblasts into myofibroblasts, which are specialized contractile cells with higher
14 profibrotic potential than fibroblasts. Within the fibroblastic foci, which define the histological usual
15 interstitial pneumonia (UIP) pattern of lung fibrosis observed in IPF, myofibroblasts cause
16 exaggerated extracellular matrix (ECM) deposit, that is the hallmark of the scarring process (14).
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

32 Pathological liver fibrosis is similarly characterized by excessive accumulation of ECM proteins,
33 (fibrillar collagens, glycoproteins and proteoglycans) and is induced by activated myofibroblasts
34 (15). Bridging fibrosis and regeneration nodes are the clearest manifestation of this injury, being
35 cirrhosis the end stage of this process (16). Excessive collagen deposition distorts the normal liver
36 tissue architecture, leading to hepatocellular dysfunction and increased hepatic resistance to blood
37 flow, which cause hepatic insufficiency and portal hypertension (17,18).
38
39
40
41
42
43
44
45
46

47 Our data show that more than one third of IPF patients have a concomitant and clinically
48 unremarkable fibrosing process in the liver. Having excluded subjects with potentially secondary
49 causes for liver diseases, our IPF cohorts seems to be affected by an idiopathic/cryptogenic liver
50 fibrosis. At baseline, IPF patients '*with*' and '*without liver fibrosis*' are homogeneous in terms of
51 clinical and functional data as well as serological tests. Of interest, patients '*with liver fibrosis*' gain
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 the diagnosis of IPF younger as compared to patients '*without liver fibrosis*', maybe because the
2 systemic involvement leads to an earlier onset of symptoms and disease awareness. Two examples
3 of potential common pathways responsible for fibrotic processes occurring in different organs were
4 proposed in the past: 1) Excessive telomere shortening, as a consequence of telomerase gene
5 mutations, ultimately leading to apoptosis and organ failure, specifically in the lung, but also in the
6 liver; 2) Germ-line mutations in telomerase components hTERT and hTR, that are found in a subset
7 (8-15%) of patients with familial pulmonary fibrosis (19,20). Moreover, as compared with age-
8 matched controls, patients with IPF have shorter telomeres regardless of whether they carry
9 telomerase-related mutations (21,22). In the liver, excessive telomere shortening, as a consequence
10 of telomerase gene mutations, may impair the hepatocyte regenerative ability in response to
11 chronic damage, thus facilitating fibrosis progression.

12 Although percutaneous biopsy has traditionally been considered as the gold standard for the
13 diagnosis and staging of chronic liver diseases, researchers have invested much efforts to develop
14 noninvasive tests able to evaluate liver fibrosis.

15 Both instrumental and serological methods to evaluate liver fibrosis were developed and validated
16 (10,23-28). Among these, HTE has been evaluated as a non-invasive method for assessing liver
17 fibrosis in a variety of chronic liver diseases while APRI is a simple index calculated with readily
18 available laboratory results that proved to identify with a high degree of accuracy the presence of
19 significant fibrosis and cirrhosis in patients with chronic HCV-related hepatitis (28). The mean liver
20 stiffness value discovered in healthy patients without overt causes of liver disease and normal liver
21 enzymes, has been estimated 5.5 ± 1.6 kPa. Age has no influence, but liver stiffness values have
22 been found higher in obese patients and males (10). Liver stiffness assessment can be difficult in
23 patients with BMI > 29 and in those with narrow intercostal space and cannot be performed in
24 patients with ascites. According to experienced reported measurements, liver stiffness cannot be

1 measured in 5-15% of cases (24-27). In our study we have observed a greater proportion of
2 unreliable measurements (22%) mainly due to either increased thickness of subcutaneous adipose
3 tissue of the chest (n=6) or narrow intercostal spaces (n=2).
4
5

6 Of great interest, our data showed that patients '*with liver fibrosis*' have a shorter survival as
7 compared to patients '*without liver fibrosis*' (median survival of 33 vs. 63 months, respectively). The
8 worst prognosis of patients with subclinical liver fibrosis opens an intriguing scenario, in the context
9 of a disease, like IPF, universally considered as being limited to the lungs.
10
11

12 These preliminary data may indicate the usefulness of a systemic approach to clarify the possible
13 correlation between the fibrotic process across lung and liver. More focused studies are needed to
14 identify cellular/molecular pathways of response to injury - if any - that are shared by liver and lung
15 fibrosis. Detection of a subgroup of patients with idiopathic fibrotic disease involving more organs,
16 would allow the definition of a new clinical phenotype, paving the way for future research. Future
17 studies may also analyze whether short telomeres may contribute to such phenotype.
18
19

20 If common pathogenetic mechanisms between lung and liver fibrosis are identified, this would
21 inevitably impact on prognosis and treatment of IPF. Indeed, concomitant liver fibrosis may
22 potentially influence response of IPF patients to antifibrotic drugs and may explain, at least in part,
23 the variable degrees of functional decline and disease progression observed in both clinical trials
24 and real-world studies of pirfenidone and nintedanib. Moreover, concomitant liver fibrosis may
25 increase patient susceptibility to liver toxicity, which is one of the most common side effects of
26 antifibrotic therapy.
27
28

29 In our population, we finally analyzed which indicators could be independent predictors of survival.
30 Our data revealed that only lower levels of APRI is an independent predictor of survival in IPF
31 patients (HR: 4.52; 95%CI: 1.30 – 15.6; p = 0.02), which is added to the predictive role of liver fibrosis.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 The findings of our study should be seen in light of some limitations. First of all, our study did not
2 include an age-matched control group. Secondly the study population is relatively small; however,
3 IPF is a rare disease, and collecting a large number of patients is challenging. Thirdly, patients with
4 BMI > 29 (n=6) were excluded due to the intrinsic limitation of the HTE technique while 5 patients
5 were excluded based on their morphotype. As a result, our findings need to be further confirmed
6 before being generalizable to the broader population of IPF patients.
7
8
9
10
11
12

13 In conclusion, our study shows that a relevant proportion of patients with IPF have also liver fibrosis;
14 whether the co-existence of the two conditions is caused by common fibrogenic pathways needs to
15 be explored further. In particular, this subset of IPF patients should be investigated for carriage of
16 telomerase mutations and telomere length. IPF has long been considered the prototypic disease
17 limited to the lung. However, if confirmed by larger studies, our data suggest that, at least in a subset
18 of patients, IPF may be part of multiorgan fibrotic phenotype.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

References

1. Sgalla G, Cocconcelli E, Tonelli R, Richeldi L. Novel drug targets for idiopathic pulmonary fibrosis. *Expert Rev Respir Med.* 2016 Apr;10(4):393-405. doi: 10.1586/17476348.2016.1152186. Epub 2016 Feb 26.
2. Wenzke KE, Cantemir-Stone C, Zhang J, Marsh CB, Huang, K. Identifying common genes and networks in multi-organ fibrosis. *AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science, 2012, 106–115.*
3. Jun JJ, Lau LF. Resolution of organ fibrosis. *J Clin Invest.* 2018;128(1):97–107.
4. Zeisberg M, Kalluri R. Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. *Am J Physiol Cell Physiol.* 2013;304(3):C216–C225. doi:10.1152/ajpcell.00328.2012.
5. Selman M, King J, Pardo A. Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy. *Ann Intern Med* 2001;134(2):136–51.
6. Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. *NEJM* 2018;29(5):283–91.
7. Raghu G, Collard HR, Egan JJ, et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med* 2011;183(6):788–824.
8. Raghu G, Remy-jardin M, Myers JL, et al. AMERICAN THORACIC SOCIETY Diagnosis of Idiopathic Pulmonary Fibrosis. 2018;198(5).
9. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS. *Annals of Internal Medicine A Multidimensional Index and Staging System for Idiopathic.* 2013;
10. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. *J Hepatol* 2008;48(5):835–47.
11. Platon ML, Stefanescu H, Feier D, Maniu A, Badea R. Performance of unidimensional transient

elastography in staging chronic hepatitis C. results from a cohort of 1,202 biopsied patients from one single center. *J Gastrointest Liver Dis* 2013;22(2):157–66.

12. Lieber CS, Weiss DG, Morgan TR, Paronetto F. Aspartate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis. *Am J Gastroenterol* 2006;101(7):1500–8.
13. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: An updated meta-analysis. *Hepatology* 2011;53(3):726–36.
14. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. *Nat Med* 2013;18(7):1028–40.
15. Friedman SL. Liver fibrosis - from bench to bedside. *J Hepatol* 2003;38 Suppl 1:S38–53.
16. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. *Semin Liver Dis* 2001;21(3):351–72.
17. Schölmerich J, Holstege A. Aetiology and Pathophysiology of Chronic Liver Disorders. *Drugs* 1990;40(3):3–22.
18. Perepelyuk M, Terajima M, Wang AY, et al. Hepatic stellate cells and portal fibroblasts are the major cellular sources of collagens and lysyl oxidases in normal liver and early after injury. *Am J Physiol - Gastrointest Liver Physiol* 2013;304(6):605–15.
19. Armanios MY, Chen JLL, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. *N Engl J Med* 2007;356(13):1317–26.
20. Armanios M. Syndromes of Telomere Shortening. *Annu Rev Genomics Hum Genet* 2009;10(1):45–61.
21. Alder JK, Cogan JD, Brown AF, et al. Ancestral mutation in telomerase causes defects in repeat addition processivity and manifests as familial pulmonary fibrosis. *PLoS Genet* 2011;7(3):1–9.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

22. Diaz de Leon A, Cronkhite JT, Katzenstein ALA, et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) Mutations. *PLoS One* 2010;5(5).

23. Sandrin L, Fourquet B, Hasquenoph J-M, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. *Ultrasound Med Biol* 2003;29(12):1705–13.

24. Colletta C, Smirne C, Fabris C, et al. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. *Hepatology* 2005;42(4):838–45.

25. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. *Gut* 2006;55(3):403–8.

26. Kettaneh A, Marcellin P, Douvin C, et al. Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. *J Hepatol* 2007;46(4):628–34.

27. Shaheen AAM, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. *Am J Gastroenterol* 2007;102(11):2589–600.

28. Wai C-T, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology* 2003;38(2):518–26.

29. Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. *Gastroenterology* 2005;128(2):343–50.

Figure legend

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 1

Parts of the whole population enrolled in the study. Grey box indicates patients with not reliable Fibroscan® measurements, light green box indicates patients without liver fibrosis and dark green box indicates patients with liver fibrosis.

Figure 2

Survival curves of IPF patients according to the presence of liver fibrosis.

Figure 3

Cumulative average survival time of IPF patients according to the presence of liver fibrosis.

Declarations

Ethics approval and consent to participate

Approval from the local ethics committee of Modena was obtained (registered protocol n. 2645). Written informed consent to participate was obtained from all patients enrolled or their relatives, when appropriate.

Consent for publication

Consent for publication was obtained from all patients enrolled.

Availability of data and materials

Data are available at the Respiratory Disease Unit of the University Hospital of Modena, Italy.

Funding

None.

Competing interests


The authors have no competing interests with any organization or entity with a financial interest in competition with the subject, matter or materials discussed in the manuscript.


Authors contributions

EC and RT made substantial contribution to the concept, design, conduction of the study and to the realization of the manuscript, thus they ought to be considered both as first author. EC, RT, SC and LR designed the study, enrolled patients and wrote the paper. GA, IC, FP and EB made substantial contributions to literature review, data collection and paper writing. AV, FPR, FL and AM reviewed the literature, wrote the manuscript and produced the figures. AP critically reviewed and edited the manuscript. PS, LR and EC designed the study and reviewed and edited the manuscript. All the authors made substantial contribution to the realization of the work and approved the final version of the manuscript.

Acknowledgments

We want to thanks Professional Editor Colin Woodham for language editing.








Table 1

Variable	
Patients – n (%)	37 (100)
Male – n (%)	26 (70)
Female – n (%)	11 (30)
Age at diagnosis – years	71 (42–83)
Smoking history – pack/years	10 (0-64)
Clinical-radiological diagnosis – n (%)	28 (76)
Histological diagnosis – n (%)	9 (24)
FVC at diagnosis – %pred.	78 (22–120)
DL_{CO} at diagnosis – %pred.	36 (11–102)
Gap score	
I	14 (38)
II	16 (43)
III	7 (19)

Table 1

Baseline characteristics of 37 IPF patients included in the study.

Table 2

Variable	Population	Without liver	With liver fibrosis	
Male – <i>n</i> (%)	21 (72)	10 (62)	11 (85)	0.23
Female – <i>n</i> (%)	8 (28)	6 (38)	2 (15)	
Age at diagnosis –	71 (42–83)	75 (42-83)	66 (54-78)	0.04
Smoking history –	10 (0-64)	3 (0-64)	21 (0-45)	0.42
Radiological	22 (76)	13 (81)	9 (69)	0.66
Histological	7 (24)	3 (19)	4 (31)	
FVC at diagnosis –	78 (22–120)	72 (22-120)	79 (45-98)	0.34
DL _{CO} at diagnosis –	35 (11–102)	38 (11-65)	35 (23-102)	0.80
GAP score				
I	11 (38)	5 (31)	6 (46)	
II	14 (48)	9 (56)	5 (39)	0.62
III	4 (14)	2 (13)	2 (15)	
Liver stiffness – <i>kPa</i>	4.50 (2.60-45.30)	3.65 (2.60-5.10)	7.60 (6.10-45.30)	< 0.0001
APRI index	0.23 (0.16-1.24)	0.25 (0.17-0.51)	0.23 (0.16-1.24)	0.78
Platelets – <i>n</i> x10 ⁹ /L	250 (156-363)	251 (157-363)	236 (156-324)	0.37
AST – U/L	20 (13-82)	20 (15-27)	22 (13-82)	0.86
ALT – U/L	15 (8-80)	14 (8-29)	28 (8-80)	0.10
γGT – U/L	21 (12-643)	20 (12-42)	42 (12-643)	0.14
Bilirubin total –	0.43 (0.24-1.45)	0.40 (0.26-0.65)	0.51 (0.24-1.45)	0.23
IgG 4 – mg/dL	52 (10-618)	52 (23-618)	96 (10-433)	0.88
Iron – umol/l	91 (19-175)	104 (86-139)	78 (19-175)	0.18
Ferritin – ug/l	99 (22-276)	92 (22-276)	135 (59-227)	0.93
Transferrin – g/L	357 (258-522)	335 (258-399)	379 (275-522)	0.48

Table 2

Baseline characteristics of the 29 IPF patients evaluated for liver stiffness, of which 16 without liver fibrosis on HTE measurements and 13 with liver fibrosis. Data are presented as number and percentage for dichotomous values or median and ranges for continuous values.

Table 3

		Univariate analysis	
		OR (95% CI)	p Value
Gender	Female	Ref.	
	Male	3.30 (0.60 - 26.26)	0.19
Age at diagnosis		0.95 (0.86 - 1.02)	0.17
FVC at diagnosis - % pred.	> 80	Ref.	
	60 – 80	0.14 (0.006 – 1.25)	0.11
	< 60	0.59 (0.10 – 3.08)	0.53
DL _{CO} at diagnosis - % pred.	> 50	Ref.	
	35 -50	0.66 (0.067 - 5.53)	0.70
	< 35	0.33 (0.03 - 2.8)	0.31
GAP score	I	Ref.	
	II	1.2 (0.11 to 13.3)	0.87
	III	0.55 (0.01 – 1.08)	0.60
Platelets - n x10 ⁹ /L		0.99 (0.98 – 1.01)	0.43
APRI index		4.98 (0.12 - 874.1)	0.42
AST – U/L		1.05 (0.97 – 1.18)	0.29
ALT – U/L		1.08 (1.01 - 1.19)	0.06
γGT – U/L		0.04 (1.00 - 1.11)	0.10
IgG 4 – mg/dL		1.00 (0.99 – 1.00)	0.63
Iron – umol/l		0.98 (0.95 – 1.00)	0.30

Table 3

Predictive factors of liver stiffness in the entire population of IPF patients evaluated for liver stiffness on Fibroscan® measurements. Values are expressed as HR (95%CI). Logistic regression analysis in relation to liver stiffness was used to determine the relationship of clinical, functional and serum levels of liver function with liver stiffness development.

Table 4

		Univariate analysis		Multivariate analysis	
		HR (95% CI)	p Value	HR (95% CI)	p Value
Gender	<i>female</i>	-	-	-	-
	<i>male</i>	1.08 (0.39 – 3.01)	0.87	-	-
Age at diagnosis (<i>years</i>)	< 71	-	-	-	-
	≥ 71	1.46 (0.57 – 3.73)	0.42	-	-
Smoking history (<i>packyears</i>)	< 10	-	-	-	-
	≥ 10	0.79 (0.25 – 2.46)	0.68	-	-
FVC at diagnosis (%)	≥ 78	-	-	-	-
	< 78	1.40 (0.506 – 3.46)	0.46	-	-
DL _{co} at diagnosis (%)	≥ 35	-	-	-	-
	< 35	3.95 (1.46 – 10.7)	0.007	3.18 (0.56 – 17.8)	0.18
GAP score	<i>I</i>	-	-	-	-
	<i>II</i>	1.26 (0.45 – 3.54)	0.66	0.42 (0.07 – 2.49)	0.33
	<i>III</i>	5,40 (1.43 – 20.4)	0.01	3.91 (0.42 – 36.3)	0.22
METAVIR score	<i>F0</i>	-	-	-	-
	<i>F1-F2-F3-F4</i>	2.60 (1.003 – 6.7)	0.04	1.39 (0.50-3.89)	0.51
Platelets - n x109/L	< 250	-	-	-	-
	≥ 250	0.85 (0.30 – 2.42)	0.76	-	-
APRI index	< 0.23	-	-	-	-
	≥ 0.23	2.39 (1.89 – 6.40)	0.01	4.52 (1.30-15.6)	0.02
AST – U/L	< 20	-	-	-	-
	≥ 20	1.54 (0.59 – 3.98)	0.37	-	-
ALT – U/L	< 15	-	-	-	-
	≥ 15	1.58 (0.62 – 4.04)	0.33	-	-
γGT – U/L	< 21	-	-	-	-
	≥ 21	2.25 (0.82 – 6.15)	0.11	-	-
Total bilirubin– umol/l	< 0.43	-	-	-	-
	≥ 0.43	2.16 (0.72 – 6.47)	0.16	-	-
IgG 4 – mg/dL	< 52	-	-	-	-
	≥ 52	0.83 (0.25 – 2.75)	0.76	-	-
Iron – umol/l	< 91	-	-	-	-
	≥ 91	0.36 (0.10 – 1.34)	0.13	-	-

Ferritin – ug/l	< 99	-	-	-	-
	≥ 99	1.57 (0.14 – 17.7)	0.71	-	-
Transferrin – g/L	< 357	-	-	-	-
	≥ 357	1.46 (0.38 – 5.56)	0.57	-	-

Table 4

Predictors of overall survival in the population of IPF patients treated with antifibrotics.

Values are expressed as HR (95%CI). Univariate and multivariate Cox proportional hazard regression tests were used to determine the relationship of clinical, functional and serological characteristics with survival.

SPRINGER NATURE

Disclosure of potential conflicts of interest

Authors must disclose all relationships or interests that could have direct or potential influence or impart bias on the work. Although an author may not feel there is any conflict, disclosure of all relationships and interests provides a more complete and transparent process, leading to an accurate and objective assessment of the work. Awareness of real or perceived conflicts of interest is a perspective to which the readers are entitled. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate. For examples of potential conflicts of interests *that are directly or indirectly related to the research please* visit:

<http://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/publishing-ethics/14214>

All authors of papers submitted to INTERNAL AND EMERGENCY MEDICINE
[include name of journal] must complete this form and disclose any real or perceived conflict of interest.

Please complete one form per author. The corresponding author collects the conflict of interest disclosure forms from all authors. The corresponding author will include a summary statement that reflects what is recorded in the potential conflict of interest disclosure form(s). Please check the Instructions for Authors where to put the statement which may be different dependent on the type of peer review used for the journal. Please note that you cannot save the form once completed. Please print upon completion, sign, and scan to keep a copy for your files.

The corresponding author should be prepared to send potential conflict of interest disclosure form if requested during peer review or after publication on behalf of all authors (if applicable).

I have no potential conflict of interest.

Category of disclosure	Description of Interest/Arrangement


Article title Subclinical Liver Fibrosis in patients with Idiopathic Pulmonary Fibrosis

Manuscript No. (if you know it) _____

Author name ELISABETTA COCCANZELLI

Are you the corresponding author? Yes No

Herewith I confirm that the information provided is accurate.

Author signature  Date 03/03/2020

SPRINGER NATURE

Disclosure of potential conflicts of interest

Authors must disclose all relationships or interests that could have direct or potential influence or impart bias on the work. Although an author may not feel there is any conflict, disclosure of all relationships and interests provides a more complete and transparent process, leading to an accurate and objective assessment of the work. Awareness of real or perceived conflicts of interest is a perspective to which the readers are entitled. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate. For examples of potential conflicts of interests *that are directly or indirectly related to the research please visit:*

<http://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/publishing-ethics/14214>

All authors of papers submitted to INTERNAL AND EMERGENCY MEDICINE
[include name of journal] must complete this form and disclose any real or perceived conflict of interest.

Please complete one form per author. The corresponding author collects the conflict of interest disclosure forms from all authors. The corresponding author will include a summary statement that reflects what is recorded in the potential conflict of interest disclosure form(s). Please check the Instructions for Authors where to put the statement which may be different dependent on the type of peer review used for the journal. Please note that you cannot save the form once completed. Please print upon completion, sign, and scan to keep a copy for your files.

The corresponding author should be prepared to send potential conflict of interest disclosure form if requested during peer review or after publication on behalf of all authors (if applicable).

I have no potential conflict of interest.

Category of disclosure	Description of Interest/Arrangement

Article title Subclinical Liver Fibrosis in patients with Idiopathic Pulmonary Fibrosis

Manuscript No. (if you know it) _____

Author name ROBERTO TONELLI

Are you the corresponding author? Yes No

Herewith I confirm that the information provided is accurate.

Author signature [Signature] Date 04/03/20

SPRINGER NATURE

Disclosure of potential conflicts of interest

Authors must disclose all relationships or interests that could have direct or potential influence or impart bias on the work. Although an author may not feel there is any conflict, disclosure of all relationships and interests provides a more complete and transparent process, leading to an accurate and objective assessment of the work. Awareness of real or perceived conflicts of interest is a perspective to which the readers are entitled. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate. For examples of potential conflicts of interests *that are directly or indirectly related to the research please visit:*

<http://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/publishing-ethics/14214>

All authors of papers submitted to INTERNAL AND EMERGENCY MEDICINE
[include name of journal] must complete this form and disclose any real or perceived conflict of interest.

Please complete one form per author. The corresponding author collects the conflict of interest disclosure forms from all authors. The corresponding author will include a summary statement that reflects what is recorded in the potential conflict of interest disclosure form(s). Please check the Instructions for Authors where to put the statement which may be different dependent on the type of peer review used for the journal. Please note that you cannot save the form once completed. Please print upon completion, sign, and scan to keep a copy for your files.

The corresponding author should be prepared to send potential conflict of interest disclosure form if requested during peer review or after publication on behalf of all authors (if applicable).

I have no potential conflict of interest.

Category of disclosure	Description of Interest/Arrangement

Article title Subclinical Liver Fibrosis in patients with Idiopathic Pulmonary Fibrosis

Manuscript No. (if you know it) _____

Author name GIANLUCA ABBATI

Are you the corresponding author? Yes No

Herewith I confirm that the information provided is accurate.

Author signature G. Abbat Date 03/03/20

SPRINGER NATURE

Disclosure of potential conflicts of interest

Authors must disclose all relationships or interests that could have direct or potential influence or impart bias on the work. Although an author may not feel there is any conflict, disclosure of all relationships and interests provides a more complete and transparent process, leading to an accurate and objective assessment of the work. Awareness of real or perceived conflicts of interest is a perspective to which the readers are entitled. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate. For examples of potential conflicts of interests *that are directly or indirectly related to the research please* visit:

<http://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/publishing-ethics/14214>

All authors of papers submitted to INTERNAL AND EMERGENCY MEDICINE
[include name of journal] must complete this form and disclose any real or perceived conflict of interest.

Please complete one form per author. The corresponding author collects the conflict of interest disclosure forms from all authors. The corresponding author will include a summary statement that reflects what is recorded in the potential conflict of interest disclosure form(s). Please check the Instructions for Authors where to put the statement which may be different dependent on the type of peer review used for the journal. Please note that you cannot save the form once completed. Please print upon completion, sign, and scan to keep a copy for your files.

The corresponding author should be prepared to send potential conflict of interest disclosure form if requested during peer review or after publication on behalf of all authors (if applicable).

I have no potential conflict of interest.

Category of disclosure	Description of Interest/Arrangement


Article title Subclinical Liver Fibrosis in patients with Idiopathic Pulmonary Fibrosis

Manuscript No. (if you know it) _____

Author name ALESSANDRO MARCHIONI

Are you the corresponding author? Yes No

Herewith I confirm that the information provided is accurate.

Author signature  Date 4/3/20

SPRINGER NATURE

Disclosure of potential conflicts of interest

Authors must disclose all relationships or interests that could have direct or potential influence or impart bias on the work. Although an author may not feel there is any conflict, disclosure of all relationships and interests provides a more complete and transparent process, leading to an accurate and objective assessment of the work. Awareness of real or perceived conflicts of interest is a perspective to which the readers are entitled. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate. For examples of potential conflicts of interests *that are directly or indirectly related to the research please visit:*

<http://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/publishing-ethics/14214>

All authors of papers submitted to INTERNAL AND EMERGENCY MEDICINE
[include name of journal] must complete this form and disclose any real or perceived conflict of interest.

Please complete one form per author. The corresponding author collects the conflict of interest disclosure forms from all authors. The corresponding author will include a summary statement that reflects what is recorded in the potential conflict of interest disclosure form(s). Please check the Instructions for Authors where to put the statement which may be different dependent on the type of peer review used for the journal. Please note that you cannot save the form once completed. Please print upon completion, sign, and scan to keep a copy for your files.

The corresponding author should be prepared to send potential conflict of interest disclosure form if requested during peer review or after publication on behalf of all authors (if applicable).

I have no potential conflict of interest.

Category of disclosure	Description of Interest/Arrangement

Article title Subclinical Liver Fibrosis in patients with Idiopathic Pulmonary Fibrosis

Manuscript No. (if you know it) _____

Author name IVANA CASTANIERE

Are you the corresponding author? Yes No

Herewith I confirm that the information provided is accurate.

Author signature Ivana Castanieri 4/3/2020

SPRINGER NATURE

Disclosure of potential conflicts of interest

Authors must disclose all relationships or interests that could have direct or potential influence or impart bias on the work. Although an author may not feel there is any conflict, disclosure of all relationships and interests provides a more complete and transparent process, leading to an accurate and objective assessment of the work. Awareness of real or perceived conflicts of interest is a perspective to which the readers are entitled. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate. For examples of potential conflicts of interests *that are directly or indirectly related to the research please visit:*

<http://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/publishing-ethics/14214>

All authors of papers submitted to INTERNAL AND EMERGENCY MEDICINE
[Include name of journal] must complete this form and disclose any real or perceived conflict of interest.

Please complete one form per author. The corresponding author collects the conflict of interest disclosure forms from all authors. The corresponding author will include a summary statement that reflects what is recorded in the potential conflict of interest disclosure form(s). Please check the instructions for Authors where to put the statement which may be different dependent on the type of peer review used for the journal. Please note that you cannot save the form once completed. Please print upon completion, sign, and scan to keep a copy for your files.

The corresponding author should be prepared to send potential conflict of interest disclosure form if requested during peer review or after publication on behalf of all authors (if applicable).

I have no potential conflict of interest.

Category of disclosure	Description of Interest/Arrangement


Article title Subclinical Liver Fibrosis in patients with Idiopathic Pulmonary Fibrosis

Manuscript No. (if you know it) _____

Author name FILIPPO PELLICANO

Are you the corresponding author? Yes No

Herewith I confirm that the information provided is accurate.

Author signature  Date 04/03/2020

SPRINGER NATURE

Disclosure of potential conflicts of interest

Authors must disclose all relationships or interests that could have direct or potential influence or impart bias on the work. Although an author may not feel there is any conflict, disclosure of all relationships and interests provides a more complete and transparent process, leading to an accurate and objective assessment of the work. Awareness of real or perceived conflicts of interest is a perspective to which the readers are entitled. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate. For examples of potential conflicts of interests *that are directly or indirectly related to the research please visit:*

<http://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/publishing-ethics/14214>

All authors of papers submitted to INTERNAL AND EMERGENCY MEDICINE
[include name of journal] must complete this form and disclose any real or perceived conflict of interest.

Please complete one form per author. The corresponding author collects the conflict of interest disclosure forms from all authors. The corresponding author will include a summary statement that reflects what is recorded in the potential conflict of interest disclosure form(s). Please check the Instructions for Authors where to put the statement which may be different dependent on the type of peer review used for the journal. Please note that you cannot save the form once completed. Please print upon completion, sign, and scan to keep a copy for your files.

The corresponding author should be prepared to send potential conflict of interest disclosure form if requested during peer review or after publication on behalf of all authors (if applicable).

I have no potential conflict of interest.

Category of disclosure	Description of Interest/Arrangement

Article title Subclinical Liver Fibrosis in patients with Idiopathic Pulmonary Fibrosis

Manuscript No. (if you know it) _____

Author name FRAZ LESCO PAOLO RUBSO

Are you the corresponding author? Yes No

Herewith I confirm that the information provided is accurate.

Author signature [Signature] Date 04/03/20

SPRINGER NATURE

Disclosure of potential conflicts of interest

Authors must disclose all relationships or interests that could have direct or potential influence or impart bias on the work. Although an author may not feel there is any conflict, disclosure of all relationships and interests provides a more complete and transparent process, leading to an accurate and objective assessment of the work. Awareness of real or perceived conflicts of interest is a perspective to which the readers are entitled. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate. For examples of potential conflicts of interests *that are directly or indirectly related to the research please visit:*

<http://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/publishing-ethics/14214>

All authors of papers submitted to INTERNAL AND EMERGENCY MEDICINE
[include name of journal] must complete this form and disclose any real or perceived conflict of interest.

Please complete one form per author. The corresponding author collects the conflict of interest disclosure forms from all authors. The corresponding author will include a summary statement that reflects what is recorded in the potential conflict of interest disclosure form(s). Please check the Instructions for Authors where to put the statement which may be different dependent on the type of peer review used for the journal. Please note that you cannot save the form once completed. Please print upon completion, sign, and scan to keep a copy for your files.

The corresponding author should be prepared to send potential conflict of interest disclosure form if requested during peer review or after publication on behalf of all authors (if applicable).

I have no potential conflict of interest.

Category of disclosure	Description of Interest/Arrangement

Article title Subclinical Liver Fibrosis in patients with Idiopathic Pulmonary Fibrosis

Manuscript No. (if you know it) _____

Author name ALBERTO VEGGETTI

Are you the corresponding author? Yes No

Herewith I confirm that the information provided is accurate.

Author signature Alberto Veggetti Date 4/3/20

SPRINGER NATURE

Disclosure of potential conflicts of interest

Authors must disclose all relationships or interests that could have direct or potential influence or impart bias on the work. Although an author may not feel there is any conflict, disclosure of all relationships and interests provides a more complete and transparent process, leading to an accurate and objective assessment of the work. Awareness of real or perceived conflicts of interest is a perspective to which the readers are entitled. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate. For examples of potential conflicts of interests *that are directly or indirectly related to the research please visit:*

<http://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/publishing-ethics/14214>

All authors of papers submitted to INTERNAL AND EMERGENCY MEDICINE
[include name of journal] must complete this form and disclose any real or perceived conflict of interest.

Please complete one form per author. The corresponding author collects the conflict of interest disclosure forms from all authors. The corresponding author will include a summary statement that reflects what is recorded in the potential conflict of interest disclosure form(s). Please check the Instructions for Authors where to put the statement which may be different dependent on the type of peer review used for the journal. Please note that you cannot save the form once completed. Please print upon completion, sign, and scan to keep a copy for your files.

The corresponding author should be prepared to send potential conflict of interest disclosure form if requested during peer review or after publication on behalf of all authors (if applicable).

I have no potential conflict of interest.

Category of disclosure	Description of Interest/Arrangement

Article title Subclinical Liver Fibrosis in patients with Idiopathic Pulmonary Fibrosis

Manuscript No. (if you know it) _____

Author name ELISABETTA BAUESTRO

Are you the corresponding author? Yes No

Herewith I confirm that the information provided is accurate.

Author signature Elisabetta Bauestro 03/04/2020

SPRINGER NATURE

Disclosure of potential conflicts of interest

Authors must disclose all relationships or interests that could have direct or potential influence or impart bias on the work. Although an author may not feel there is any conflict, disclosure of all relationships and interests provides a more complete and transparent process, leading to an accurate and objective assessment of the work. Awareness of real or perceived conflicts of interest is a perspective to which the readers are entitled. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate. For examples of potential conflicts of interests *that are directly or indirectly related to the research please* visit:

<http://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/publishing-ethics/14214>

All authors of papers submitted to INTERNAL AND EMERGENCY MEDICINE [include name of journal] must complete this form and disclose any real or perceived conflict of interest.

Please complete one form per author. The corresponding author collects the conflict of interest disclosure forms from all authors. The corresponding author will include a summary statement that reflects what is recorded in the potential conflict of interest disclosure form(s). Please check the Instructions for Authors where to put the statement which may be different dependent on the type of peer review used for the journal. Please note that you cannot save the form once completed. Please print upon completion, sign, and scan to keep a copy for your files.

The corresponding author should be prepared to send potential conflict of interest disclosure form if requested during peer review or after publication on behalf of all authors (if applicable).

I have no potential conflict of interest.

Category of disclosure	Description of Interest/Arrangement


Article title Subclinical Liver Fibrosis in patients with Idiopathic Pulmonary Fibrosis

Manuscript No. (if you know it) _____

Author name ANTONELLO PIETRANGELO

Are you the corresponding author? Yes No

Herewith I confirm that the information provided is accurate.

Author signature , Date 03/04/2020

SPRINGER NATURE

Disclosure of potential conflicts of interest

Authors must disclose all relationships or interests that could have direct or potential influence or impart bias on the work. Although an author may not feel there is any conflict, disclosure of all relationships and interests provides a more complete and transparent process, leading to an accurate and objective assessment of the work. Awareness of real or perceived conflicts of interest is a perspective to which the readers are entitled. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate. For examples of potential conflicts of interests *that are directly or indirectly related to the research please visit:*

<http://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/publishing-ethics/14214>

All authors of papers submitted to INTERNAL AND EMERGENCY MEDICINE
[include name of journal] must complete this form and disclose any real or perceived conflict of interest.

Please complete one form per author. The corresponding author collects the conflict of interest disclosure forms from all authors. The corresponding author will include a summary statement that reflects what is recorded in the potential conflict of interest disclosure form(s). Please check the Instructions for Authors where to put the statement which may be different dependent on the type of peer review used for the journal. Please note that you cannot save the form once completed. Please print upon completion, sign, and scan to keep a copy for your files.

The corresponding author should be prepared to send potential conflict of interest disclosure form if requested during peer review or after publication on behalf of all authors (if applicable).

I have no potential conflict of interest.

Category of disclosure	Description of Interest/Arrangement


Article title Subclinical Liver Fibrosis in patients with Idiopathic Pulmonary Fibrosis

Manuscript No. (if you know it) _____

Author name LUCA RICHELDI

Are you the corresponding author? Yes No

Herewith I confirm that the information provided is accurate.

Author signature  Date 04/03/2020

SPRINGER NATURE

Disclosure of potential conflicts of interest

Authors must disclose all relationships or interests that could have direct or potential influence or impart bias on the work. Although an author may not feel there is any conflict, disclosure of all relationships and interests provides a more complete and transparent process, leading to an accurate and objective assessment of the work. Awareness of real or perceived conflicts of interest is a perspective to which the readers are entitled. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate. For examples of potential conflicts of interests *that are directly or indirectly related to the research please* visit:

<http://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/publishing-ethics/14214>

All authors of papers submitted to INTERNAL AND EMERGENCY MEDICINE
[include name of journal] must complete this form and disclose any real or perceived conflict of interest.

Please complete one form per author. The corresponding author collects the conflict of interest disclosure forms from all authors. The corresponding author will include a summary statement that reflects what is recorded in the potential conflict of interest disclosure form(s). Please check the Instructions for Authors where to put the statement which may be different dependent on the type of peer review used for the journal. Please note that you cannot save the form once completed. Please print upon completion, sign, and scan to keep a copy for your files.

The corresponding author should be prepared to send potential conflict of interest disclosure form if requested during peer review or after publication on behalf of all authors (if applicable).

I have no potential conflict of interest.

Category of disclosure	Description of Interest/Arrangement


Article title Subclinical Liver Fibrosis in patients with Idiopathic Pulmonary Fibrosis

Manuscript No. (if you know it) _____

Author name FABRIZIO LUZZI

Are you the corresponding author? Yes No

Herewith I confirm that the information provided is accurate.

Author signature  Date 3/24/20

SPRINGER NATURE

Disclosure of potential conflicts of interest

Authors must disclose all relationships or interests that could have direct or potential influence or impart bias on the work. Although an author may not feel there is any conflict, disclosure of all relationships and interests provides a more complete and transparent process, leading to an accurate and objective assessment of the work. Awareness of real or perceived conflicts of interest is a perspective to which the readers are entitled. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate. For examples of potential conflicts of interests *that are directly or indirectly related to the research please visit:*

<http://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/publishing-ethics/14214>

All authors of papers submitted to INTERNAL AND EMERGENCY MEDICINE
[*include name of journal*] must complete this form and disclose any real or perceived conflict of interest.

Please complete one form per author. The corresponding author collects the conflict of interest disclosure forms from all authors. The corresponding author will include a summary statement that reflects what is recorded in the potential conflict of interest disclosure form(s). Please check the instructions for Authors where to put the statement which may be different dependent on the type of peer review used for the journal. Please note that you cannot save the form once completed. Please print upon completion, sign, and scan to keep a copy for your files.

The corresponding author should be prepared to send potential conflict of interest disclosure form if requested during peer review or after publication on behalf of all authors (if applicable).

I have no potential conflict of interest.

Category of disclosure	Description of Interest/Arrangement

Article title Subclinical Liver Fibrosis in patients with Idiopathic Pulmonary Fibrosis

Manuscript No. (if you know it) _____

Author name PAOLO SPAGNOLO

Are you the corresponding author? Yes No

Herewith I confirm that the information provided is accurate.

Author signature  Date 03/03/2020

Disclosure of potential conflicts of interest

Authors must disclose all relationships or interests that could have direct or potential influence or impart bias on the work. Although an author may not feel there is any conflict, disclosure of all relationships and interests provides a more complete and transparent process, leading to an accurate and objective assessment of the work. Awareness of real or perceived conflicts of interest is a perspective to which the readers are entitled. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate. For examples of potential conflicts of interests *that are directly or indirectly related to the research please* visit:

<http://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/publishing-ethics/14214>

All authors of papers submitted to INTERNAL AND EMERGENCY MEDICINE
[include name of journal] must complete this form and disclose any real or perceived conflict of interest.

Please complete one form per author. The corresponding author collects the conflict of interest disclosure forms from all authors. The corresponding author will include a summary statement that reflects what is recorded in the potential conflict of interest disclosure form(s). Please check the Instructions for Authors where to put the statement which may be different dependent on the type of peer review used for the journal. Please note that you cannot save the form once completed. Please print upon completion, sign, and scan to keep a copy for your files.

The corresponding author should be prepared to send potential conflict of interest disclosure form if requested during peer review or after publication on behalf of all authors (if applicable).

I have no potential conflict of interest.

Category of disclosure	Description of Interest/Arrangement


Article title Subclinical Liver Fibrosis in patients with Idiopathic Pulmonary Fibrosis

Manuscript No. (if you know it) _____

Author name Enrico CLINI

Are you the corresponding author? Yes No

Herewith I confirm that the information provided is accurate.

Author signature  Date 4th March 2020

SPRINGER NATURE

Disclosure of potential conflicts of interest

Authors must disclose all relationships or interests that could have direct or potential influence or impart bias on the work. Although an author may not feel there is any conflict, disclosure of all relationships and interests provides a more complete and transparent process, leading to an accurate and objective assessment of the work. Awareness of real or perceived conflicts of interest is a perspective to which the readers are entitled. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate. For examples of potential conflicts of interests *that are directly or indirectly related to the research please visit:*

<http://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/publishing-ethics/14214>

All authors of papers submitted to INTERNAL AND EMERGENCY MEDICINE
[include name of journal] must complete this form and disclose any real or perceived conflict of interest.

Please complete one form per author. The corresponding author collects the conflict of interest disclosure forms from all authors. The corresponding author will include a summary statement that reflects what is recorded in the potential conflict of interest disclosure form(s). Please check the Instructions for Authors where to put the statement which may be different dependent on the type of peer review used for the journal. Please note that you cannot save the form once completed. Please print upon completion, sign, and scan to keep a copy for your files.

The corresponding author should be prepared to send potential conflict of interest disclosure form if requested during peer review or after publication on behalf of all authors (if applicable).

I have no potential conflict of interest.

Category of disclosure	Description of Interest/Arrangement

Article title Subclinical Liver Fibrosis in patients with Idiopathic Pulmonary Fibrosis

Manuscript No. (if you know it) _____

Author name STEFANIA CERRI

Are you the corresponding author? Yes No

Herewith I confirm that the information provided is accurate.

Author signature Stefania Cerri Date 03/03/2020